Jove
Visualize
Contact Us

Related Experiment Videos

Entacapone.

B S Chong1, T L Mersfelder

  • 1Department of Pharmacy Practice, College of Pharmacy, Medical University of South Carolina, Charleston 29425, USA. chongbs@musc.edu

The Annals of Pharmacotherapy
|September 12, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A protocol for the Development of Core Outcome Sets for Endodontic Treatment modalities (COSET): an international consensus process.

Trials·2021
Same author

The development of European Society of Endodontology S3-level guidelines for the treatment of pulpal and apical disease.

International endodontic journal·2021
Same author

Chlorhexidine hypersensitivity.

British dental journal·2021
Same author

Comparison of two case difficulty assessment methods on cohorts of undergraduate dental students - a multi-centre study.

International endodontic journal·2020
Same author

Preferred Reporting Items for study Designs in Endodontology (PRIDE): guiding authors to identify and correct reporting deficiencies in their manuscripts prior to peer review.

International endodontic journal·2020
Same author

PRICE 2020 guidelines for reporting case reports in Endodontics: explanation and elaboration.

International endodontic journal·2020
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
Same journal

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.

The Annals of pharmacotherapy·2026
Same journal

A Comparison of Phenobarbital Dosing Strategies for the Treatment of Alcohol Withdrawal Syndrome.

The Annals of pharmacotherapy·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Entacapone, a new catechol-O-methyltransferase inhibitor, effectively manages Parkinson's disease by extending levodopa's motor response. This drug is recommended as an add-on therapy for patients experiencing end-of-dose wearing-off effects.

Area of Science:

  • Pharmacology
  • Neuroscience

Background:

  • Parkinson's disease (PD) is a progressive neurodegenerative disorder.
  • Levodopa/carbidopa therapy is a cornerstone treatment for PD, but efficacy can wane over time, leading to end-of-dose wearing-off phenomena.

Purpose of the Study:

  • To review the pharmacology, pharmacodynamics, pharmacokinetics, clinical efficacy, and safety of entacapone.
  • To discuss the role of entacapone as an adjunct therapy in Parkinson's disease management.

Main Methods:

  • A comprehensive literature search of MEDLINE (1966-December 1999) was conducted.
  • English-language articles, including recent studies, abstracts, and reviews, were identified using keywords such as entacapone, OR-611, catechol-O-methyltransferase inhibitor, and Parkinson's disease.
  • Human clinical trials were reviewed to summarize key findings.

Related Experiment Videos

Main Results:

  • Entacapone is a novel catechol-O-methyltransferase (COMT) inhibitor used adjunctively with levodopa/carbidopa in Parkinson's disease.
  • Entacapone increases levodopa bioavailability, prolongs motor response duration, and reduces motor fluctuations.
  • The recommended dosage is 200 mg orally with each levodopa/carbidopa dose, up to eight times daily. Common side effects include dyskinesia and gastrointestinal issues.

Conclusions:

  • Entacapone is a valuable therapeutic option for Parkinson's disease patients experiencing end-of-dose wearing-off.
  • Consideration of entacapone as add-on therapy can improve motor symptom control in PD management.